Skip to main content

"United Therapeutics has temporarily stopped enrolling patients in ongoing clinical trials of treprostinil-based therapies for pulmonary arterial hypertension (PAH) amid the COVID-19 pandemic, the company announced.

Treprostinil is a man-made version of the hormone prostacyclin, a natural compound that helps blood vessels relax and widen, prevents arteries from blocking, and improves blood flow.

United Therapeutics is a developer of treprostinil-based therapies for PAH, including Tyvaso, an inhaled formulation of treprostinil, Remodulin, administered as an injection under the skin (subcutaneously) or into a vein (intravenously); and Orenitram, an extended-release oral formulation of treprostinil.

No shortages in these medications are expected, with supplies adequate to meet demand, it added.

Ongoing clinical PH trials continue as planned, but most have paused new patient recruitment due to COVID-19. “As such, we expect that completion and data readouts for several of our ongoing and planned studies will be delayed,” the company stated in a press release."

Read more here.